Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice

Science Translational Medicine

Volumn 5, Issue 203, 2013, Pages

  Garcia, Stéphanie ^a,b,c   Dirat, Béatrice ^a,c   Tognacci, Thomas ^a,c   Rochet, Nathalie ^d   Mouska, Xavier ^d   Bonnafous, Stéphanie ^a,c,e   Patouraux, Stéphanie ^a,b,e   Tran, Albert ^a,c,e   Gual, Philippe ^a,c,e   Marchand Brustel, Yannick Le ^a,c   Gennero, Isabelle ^f   Gouze, Elvire ^a,c  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d CNRS   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ACHONDROPLASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY HEIGHT; BONE GROWTH; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GROWTH PLATE; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MALE; MORTALITY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SKULL MALFORMATION; SPINE MALFORMATION;

ACHONDROPLASIA; ANIMALS; BONE DEVELOPMENT; FEMALE; HUMANS; MALE; MICE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION;

EID: 84884676713     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006247     Document Type: Article

References (30)

1. D. M. Ornitz, FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev. 16, 205-213 (2005).
2. W. A. Horton, G. P. Lunstrum, Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. Rev. Endocr. Metab. Disord. 3, 381-385 (2002).
3. M. J. Wright, M. D. Irving, Clinical management of achondroplasia. Arch. Dis. Child. 97, 129-134 (2012).
4. W. A. Horton, J. G. Hall, J. T. Hecht, Achondroplasia. Lancet 370, 162-172 (2007).
5. E. D. Shirley, M. C. Ain, Achondroplasia: Manifestations and treatment. J. Am. Acad. Orthop. Surg. 17, 231-241 (2009).
6. F. Rousseau, J. Bonaventure, L. Legeai-Mallet, A. Pelet, J. M. Rozet, P. Maroteaux, M. Le Merrer, A. Munnich, Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252-254 (1994).
7. G. A. Bellus, T. W. Hefferon, R. I. Ortiz de Luna, J. T. Hecht, W. A. Horton, M. Machado, I. Kaitila, I. McIntosh, C. A. Francomano, Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am. J. Hum. Genet. 56, 368-373 (1995).
8. R. Shiang, L. M. Thompson, Y. Z. Zhu, D. M. Church, T. J. Fielder, M. Bocian, S. T. Winokur, J. J. Wasmuth, Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335-342 (1994).
9. F. Rousseau, J. Bonaventure, L. Legeai-Mallet, A. Pelet, J. M. Rozet, P. Maroteaux, M. LeMerrer, A. Munnich, Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Horm. Res. 45, 108-110 (1996).
10. E. Monsonego-Ornan, R. Adar, T. Feferman, O. Segev, A. Yayon, The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol. Cell. Biol. 20, 516-522 (2000).
11. D. Harada, Y. Yamanaka, K. Ueda, R. Nishimura, T. Morishima, Y. Seino, H. Tanaka, Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCγ-activated STAT1. Bone 41, 273-281 (2007).
12. E. Monsonego-Ornan, R. Adar, E. Rom, A. Yayon, FGF receptors ubiquitylation: Dependence on tyrosine kinase activity and role in downregulation. FEBS Lett. 528, 83-89 (2002).
13. M. K. Webster, D. J. Donoghue, Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15, 520-527 (1996).
14. C. Deng, A. Wynshaw-Boris, F. Zhou, A. Kuo, P. Leder, Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921 (1996).
15. S. Garofalo, M. Kliger-Spatz, J. L. Cooke, O. Wolstin, G. P. Lunstrum, S. M. Moshkovitz, W. A. Horton, A. Yayon, Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. J. Bone Miner. Res. 14, 1909-1915 (1999).
16. D. Davidson, A. Blanc, D. Filion, H. Wang, P. Plut, G. Pfeffer, M. D. Buschmann, J. E. Henderson, Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J. Biol. Chem. 280, 20509-20515 (2005).
17. M. C. Naski, J. S. Colvin, J. D. Coffin, D. M. Ornitz, Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125, 4977-4988 (1998).
18. J. P. Louboutin, B. A. Reyes, L. Agrawal, E. Van Bockstaele, D. S. Strayer, Strategies for CNS-directed gene delivery: In vivo gene transfer to the brain using SV40-derived vectors. Gene Ther. 14, 939-949 (2007).
19. L. R. Rodino-Klapac, C. L. Montgomery, W. G. Bremer, K. M. Shontz, V. Malik, N. Davis, S. Sprinkle, K. J. Campbell, Z. Sahenk, K. R. Clark, C. M. Walker, J. R. Mendell, L. G. Chicoine, Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol. Ther. 18, 109-117 (2010).
20. N. Laws, A. Hoey, Progression of kyphosis in mdx mice. J. Appl. Physiol. 97, 1970-1977 (2004).
21. Y. Xie, N. Su, M. Jin, H. Qi, J. Yang, C. Li, X. Du, F. Luo, B. Chen, Y. Shen, H. Huang, C. J. Xian, C. Deng, L. Chen, Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia. Hum. Mol. Genet. 21, 3941-3955 (2012).
22. A. Yasoda, H. Kitamura, T. Fujii, E. Kondo, N. Murao, M. Miura, N. Kanamoto, Y. Komatsu, H. Arai, K. Nakao, Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 150, 3138-3144 (2009).
23. P. J. Hunt, A. M. Richards, E. A. Espiner, M. G. Nicholls, T. G. Yandle, Bioactivity and metabolism of C-type natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 78, 1428-1435 (1994).
24. F. Lorget, N. Kaci, J. Peng, C. Benoist-Lasselin, E. Mugniery, T. Oppeneer, D. J. Wendt, S. M. Bell, S. Bullens, S. Bunting, L. S. Tsuruda, C. A. O'Neill, F. Di Rocco, A. Munnich, L. Legeai-Mallet, Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am. J. Hum. Genet. 91, 1108-1114 (2012).
25. M. Jin, Y. Yu, H. Qi, Y. Xie, N. Su, X. Wang, Q. Tan, F. Luo, Y. Zhu, Q. Wang, X. Du, C. J. Xian, P. Liu, H. Huang, Y. Shen, C. X. Deng, D. Chen, L. Chen, A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum. Mol. Genet. 21, 5443-5455 (2012).
26. J. Placone, K. Hristova, Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET. PLoS One 7, e46678 (2012).
27. L. He, N. Shobnam, W. C. Wimley, K. Hristova, FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism. J. Biol. Chem. 286, 13272-13281 (2011).
28. M. Terada, A. Shimizu, N. Sato, S. I. Miyakaze, H. Katayama, M. Kurokawa-Seo, Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs. Mol. Cell Biol. Res. Commun. 4, 365-373 (2001).
29. P. L. Toutain, A. Bousquet-Mélou, Plasma terminal half-life. J. Vet. Pharmacol. Ther. 27, 427-439 (2004).
30. A. Bertola, T. Ciucci, D. Rousseau, V. Bourlier, C. Duffaut, S. Bonnafous, C. Blin-Wakkach, R. Anty, A. Iannelli, J. Gugenheim, A. Tran, A. Bouloumié, P. Gual, A. Wakkach, Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes 61, 2238-2247 (2012).